Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter ... Third-quarter sales of HIV drug Biktarvy ...

Gilead Sciences Inc (NASDAQ:GILD) recently filed its 10-Q report ... This growth is largely due to higher demand and average ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

Gilead Sciences ( (GILD) ) has released its Q3 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Gilead Sciences easily beat third-quarter forecasts late Wednesday, and raised its outlook in a move that could bolster ...

Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen ...